Patented Medicine Prices Review Board
Symbol of the Government of Canada

 

www.pmprb-cepmb.gc.ca

Skip to content | Skip to institutional links

Common menu bar links

  • Français
  • Home
  • Contact Us
  • Help
  • Search
  • canada.gc.ca

Home > Publications > Advisory Notes

Institutional links

About PMPRB
Frequently Asked Questions
Frequently Requested Items
Legislation, Regulations and Guidelines
Regulatory
Regulatory Filings
Reporting
Consultations
Publications
Advisory Notes
Annual Reports
Articles
NEWSletter
Speech Series
Study Series and Discussion Papers
Summary of Board Meetings
Non-Patented Prescription Drug Prices Quarterly Reports
Archives
Reports to Parliament

 

Hospitality and Travel Expenses
Contracts
Disclosure of Position Reclassifications
Grant and Contribution Awards Over $25,000

Advisory Notes

Advisory Notes provide information on the PMPRB price review process and patented medicines:

  • INOtherapy - INO Therapeutics Inc. (June 2006) (PDF)
  • HEPSERA - Gilead (July 2005) (PDF)
  • REZULIN - Parke Davis (May 1999) (PDF)

Return to Publications


Date Modified: 2008-12-23

Top of Page
Important Notices